Mark A. Demitrack

Mark A. Demitrack's Title

Dr. Mark A. Demitrack currently holds the prestigious position of Senior Vice President and Chief Medical Officer. His extensive experience and leadership in the field of clinical neuroscience research underscore his expertise and authority within the industry. As a board-certified psychiatrist, Dr. Demitrack brings a wealth of knowledge and a strategic vision to his role, driving advancements in medical and clinical practices.

Mark A. Demitrack's Education and Expertise

Dr. Mark A. Demitrack's educational journey began with a BA in Physics from Columbia University, followed by an MD from the Robert Wood Johnson Medical School in New Jersey. He further honed his expertise through a psychiatry residency at the University of California-San Francisco and a research fellowship in clinical neuroendocrinology at the National Institute of Mental Health. With over thirty years of experience in both academic and industry settings, Dr. Demitrack is a recognized expert in clinical neuroscience research, specializing in mood disorders and neuroendocrine pathophysiology.

Mark A. Demitrack's Background

Dr. Demitrack's career spans significant roles in both academia and the pharmaceutical industry. He served as a faculty member at the University of Michigan Medical School, directing the Michigan Eating Disorders Program and conducting federally funded research on neuroendocrine pathophysiology. In the industry, he has held influential positions, including Vice President and Chief Medical Officer at Neuronetics, where he led the clinical development of the NeuroStar TMS Therapy System, and Vice President of Clinical Strategy at Roivant Sciences. His work has been pivotal in the post-marketing clinical development of Effexor XR and the initial NDA submission for duloxetine (Cymbalta).

Mark A. Demitrack's Achievements

Throughout his illustrious career, Dr. Mark A. Demitrack has made significant contributions to the field of psychiatry and clinical neuroscience. He has published over 100 articles, book chapters, and reviews on the pathophysiology and treatment of mood disorders and related conditions. His leadership in the development and introduction of the NeuroStar TMS Therapy System has been particularly noteworthy. As a Fellow of the American Psychiatric Association and a Member of the American College of Neuropsychopharmacology, Dr. Demitrack continues to influence the field through his research, publications, and clinical innovations.

Mark A. Demitrack's Company

Dr. Demitrack has been associated with several prominent companies throughout his career. Notably, he served as Vice President and Chief Medical Officer at Neuronetics, Inc., where he led the clinical development of the NeuroStar TMS Therapy System, a significant advancement in the treatment of depression. He also held the position of Vice President of Clinical Strategy at Roivant Sciences, contributing to the company's strategic clinical initiatives. His expertise has been instrumental in shaping the clinical strategies and development programs at these organizations, enhancing their contributions to the field of psychiatry and clinical neuroscience.